TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening plasma HIV-1 RNA ≥500 copies/mL~* ART-experienced, INI-experienced, DTG naïve~* Experienced virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen~* The subject's HIV-1 shows resistance to RAL or ELV at Screening or at prior time point of virological failure on RAL or ELV~* Documented resistance to at least one drug from each of three or more of all approved classes of ART~* Be able to receive at least one fully active drug as part of the OBR from Day 8~* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)~* Willing and able to understand and provide signed and dated written informed consent prior to Screening.~Exclusion Criteria:~* Women who are pregnant or breast feeding~* An active AIDS-defining condition at Screening (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ \<200c/mm3)~* Moderate to severe hepatic impairment as defined by Child-Pugh classification~* Anticipated need for HCV therapy during the first 24 weeks of the study~* Recent history of any upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding~* Allergy or intolerance to the study drugs or their components or drugs of their class~* Malignancy within the past 6 months~* Treatment with an HIV-1 therapeutic vaccine within 90 days of Screening~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening~* Treatment with any agent, other than licensed ART, with documented activity against HIV-1 in vitro within 28 days of first dose of investigational product~* Treatment with etravirine, efavirenz, or nevirapine within 14 days of Day 1(etravirine may be used if coadministered with lopinivir/ritonavir or darunavir/ritonavir)~* Treatment with tipranivir/ritonavir, fosamprenavir, or fosamprenavir/ritonavir within 28 days prior to Screening~* Verified Grade 4 laboratory abnormality at Screening~* ALT\> 5 times the upper limit of normal (ULN) at Screening~* ALT ≥ 3X ULN and bilirubin \> 1.5 X ULN (with 35% direct bilirubin) at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dolutegravir (Type: EXPERIMENTAL): dolutegravir plus background antiretroviral therapy optimised at Day 8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing a thyroid surgery~* male/female~* from the age of 18 until 65~* ASA physical status of I-III~* Knowledge of French, English or Dutch is required in order to be enrolled in this study.~Exclusion Criteria:~* Pregnancy~* hypo-/hyperthyroidism~* gastro-duodenal ulcer~* allergy or contraindications to one of the study drugs~* renal insufficiency~* liver insufficiency~* neuropsychiatric disturbance~* BMI \>30~* history of drug and alcohol abuse~* preoperative analgesic drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -\> 1.4 -\> 1 -\> 0.7-\> 0.5 -\> 0.35 -\> 0.25 -\> 0 ng/ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genotype 1 or 4 chronic HCV infection~* Have received a kidney transplant more than 6 months before the Baseline visit~* Cirrhosis determination~* Screening laboratory parameters within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain -resolved skin cancers)~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Planned or anticipated second kidney transplant~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 wk (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 12 weeks.
- LDV/SOF 24 wk (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Aged ≥ 3 months at the screening visit to \< 24 months on baseline/Day 1, diagnosed with AD~Exclusion Criteria:~Subjects with any clinically significant dermatological condition or disease (including active or potentially recurrent non-AD dermatological conditions that overlap with AD such as Netherton Syndrome)

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- Crisaborole ointment 2% (Type: EXPERIMENTAL): Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have received two vaccinations in study IC51 322. (2) Subjects who were enrolled as part of the immunogenicity subgroup of study IC51-322.~* Male or female healthy subjects aged ≥ 9 months to \< 21 years at the time of enrolment into this study.~* Written informed consent by the subject, the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable.~Exclusion Criteria:~* History of or clinical manifestation of any Flavivirus disease during study IC51-322.~* Vaccination against JE virus (JEV) (except with IC51) at any time prior or planned during this study.~* Participation in another study with an investigational product during study IC51-322 or IC51-324.~* History of or development of any immunodeficiency including post-organtransplantation after inclusion into study IC51-322.~* History of or development of an autoimmune disease during study IC51-322.~* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying medications started during study IC51-322 up to first visit of study IC51-324. (For corticosteroids this means prednisone or equivalent at \>= 0.05 mg/kg/day. Topical or inhaled steroids are allowed).~* Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).~* Illicit drug use and/or a history of drug or alcohol addiction and/or current drug or alcohol addiction.~* Inability or unwillingness by the legal representative(s) and/or the subject (where applicable) to provide informed consent/assent and to abide by the requirements of the study.~* Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- No treatment (Type: OTHER): subjects will be followed up on immunity (analysis of blood samples) and safety

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of focal vitreomacular adhesion (i.e., central vitreal adhesion within 6 mm Optical Coherence Tomography (OCT) field surrounded by elevation of the posterior vitreous cortex) that in the opinion of the Investigator is related to decreased visual function (such as metamorphopsia, decreased visual acuity, or other visual complaint)~Exclusion Criteria:~* Any evidence of proliferative retinopathy (including Proliferative Diabetic Retinopathy (PDR)) or other ischemic retinopathies involving vitreoretinal vascular proliferation) or exudative Age-Related Macular Degeneration (AMD) or retinal vein occlusion in the study eye~* Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye~* Subjects with macular hole diameter \> 400 µm in the study eye~* Aphakia in the study eye~* High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length \>28 mm is an exclusion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ocriplasmin 125µg (Type: EXPERIMENTAL): 125µg of ocriplasmin intravitreal injection
- Placebo (Type: PLACEBO_COMPARATOR): Intravitreal injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female aged 18 - 49 years or \>= 65 years~* Give written informed consent~* Females have a negative urine test for pregnancy before vaccination and use birth control during 28 day study period~* Willing to receive the unlicensed (VAX128) vaccine given as an i.m. injection~* Willing to provide multiple blood specimens collected by venipuncture~Exclusion Criteria:~* Chronic illness that would interfere with the subject's participation in the study or interpretation of the study results.~* Impaired immune responsiveness~* Received drugs effecting the immunity~* Received or plan to receive a nonstudy vaccine within 30 days prior to vaccination and during the study, including licensed influenza vaccines.~* History of anaphylactic type reaction to injected vaccines.~* History of drug abuse in the year prior to screening.~* History of Guillain-Barré Syndrome.~* Receipt or donation of blood products~* Acute disease within 72 hours prior to vaccination~* History of heart or lung disease~* Has other conditions that might interfere with study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VAX128 (Type: EXPERIMENTAL): Novel H1N1 Influenza vaccine
- Placebo (Type: PLACEBO_COMPARATOR): one IM injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Japanese participants ≥20 years of age~* Receiving chronic maintenance hemodialysis for end-stage kidney disease~* Hemoglobin (Hb) \<10.0 grams per deciliter (g/dL)~Exclusion Criteria:~* Anemia due to a cause other than chronic kidney disease (CKD) or presence of active bleeding or recent blood loss~* Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia~* Red blood cell transfusion within 4 weeks prior to or during screening~* Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat, Dose 1 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 2 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 3 (Type: EXPERIMENTAL): Daily oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Daily oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HPV Vaccination Study in Postpartum Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants biologically born as females between the ages of 15 through 45 who have delivered a live born baby within the past 72 hours.~Exclusion Criteria:~* Pregnancy~* Severe allergic reaction to vaccine components~* Prior receipt of an HPV vaccine dose~* Fetal demise or stillbirth~* Allergy to latex or yeast~* Moderate or severe acute illness (deemed by the investigator to exclude)~* Immunosuppression (e.g., HIV, solid organ transplant).

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Gardasil9 (Type: EXPERIMENTAL): Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being aged between 18 and 70 years old.~* Meeting the DSM-IV diagnosis criteria of emotional disorder (panic disorder with or without agoraphopia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, major depression disorder and dysthimia).~* Providing written, informed consent.~* Being able to understand and read Spanish.~* Having daily acces to the Internet in their natural environment.~Exclusion Criteria:~* Being diagnosed a severe mental disorder (people with the following mental disorders will be excluded from the study: schizophrenia, bipolar disorder and personality disorders from clusters A and B).~* Being diagnosed an alcohol and/or substance dependence disorder.~* The presence of high suicidal risk.~* A medical disease or condition which prevent the participant from carry out the psychological treatment.~* Receiving another psychological treatment while the study is still ongoing.~* The increase and/or changes in the medication of participants receiving pharmacological treament during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Transdiagnostic Internet-based Treatment (Type: EXPERIMENTAL): Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
- Treatment as Usual (Type: EXPERIMENTAL): Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Psychotherapy Development Study for Internet Gaming

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* parent/guardian of a 10-19 year old residing in the same household \>8 months/year~* reports significant problems with game playing~Exclusion Criteria:~* have a condition that may hinder study participation

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Referral for care (Type: ACTIVE_COMPARATOR): Referral for mental health issues and family support services
- Behavioral therapy (Type: EXPERIMENTAL): 8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 years of age or older~* Main active disease of the ileal, ileocecal region, and/or ascending colon - - If treated with partial nutrition treatment (≤1200 kcal/day) or if treated with azathioprine (≤2.0 mg/kg/day) or 6-mercaptopurine (≤1.2 mg/kg/day), prior to randomisation until the study completion or discontinuation~* Ability to read, write and to fill a diary card and HRQL questionnaire Having mild to moderate active Crohn's disease, defined as CDAI score of 180-400 at baseline~Exclusion Criteria:~* Patient with CD lesion or status which may affect the evaluation of the efficacy (e.g. lesion only in the upper G-I, active anorectal lesion, abscess formation, stenosis, fistulae, ostomy, short bowel or other uncontrolled concomitant disease)~* Patient who need any concomitant treatment for CD that may affect the assessment for efficacy of the study drug~* Patient who need any medication which is prohibited due to suspected influence to metabolism of the study drug~* Patient who is judged to be inadequate to participate in this study from the safety point of view Patient with well-founded doubt about protocol violation

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- D9421-C (Type: EXPERIMENTAL): D9421-C 9 mg once daily
- Mesalazine (Type: ACTIVE_COMPARATOR): Mesalazine 1 g three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete